Technical Analysis for APRE - Aprea Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 30.99 -4.65% -1.51
APRE closed down 4.65 percent on Friday, April 3, 2020, on 53 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical APRE trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
NR7 Range Contraction -4.65%
Earnings Movers Other -4.65%
20 DMA Resistance Bearish -4.03%
180 Bearish Setup Bearish Swing Setup -4.03%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.03%
Earnings Movers Other -4.03%
20 DMA Resistance Bearish -10.85%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -10.85%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Biopharmaceutical Cancer Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Lactams Myelodysplastic Syndromes Anti Cancer Therapies P53 Tumor Suppressor Tumor Suppressor Genes

Is APRE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 53.11
52 Week Low 15.1
Average Volume 84,845
200-Day Moving Average 0.00
50-Day Moving Average 35.03
20-Day Moving Average 34.16
10-Day Moving Average 33.76
Average True Range 4.30
ADX 15.68
+DI 12.35
-DI 19.65
Chandelier Exit (Long, 3 ATRs ) 28.19
Chandelier Exit (Short, 3 ATRs ) 39.29
Upper Bollinger Band 38.74
Lower Bollinger Band 29.59
Percent B (%b) 0.15
BandWidth 26.78
MACD Line -0.77
MACD Signal Line -0.47
MACD Histogram -0.3025
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 34.58
Resistance 3 (R3) 34.69 33.60 33.98
Resistance 2 (R2) 33.60 32.69 33.55 33.78
Resistance 1 (R1) 32.30 32.13 31.76 32.19 33.58
Pivot Point 31.21 31.21 30.94 31.16 31.21
Support 1 (S1) 29.91 30.30 29.37 29.80 28.40
Support 2 (S2) 28.82 29.74 28.77 28.20
Support 3 (S3) 27.52 28.82 28.00
Support 4 (S4) 27.41